Latest stories on SNDX
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha55 · neutralgeneral
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Syndax Announces Participation in September Investor Conferences
Business Insider55 · neutralgeneral
Syndax Announces Participation in September Investor Conferences
GlobeNewswire56 · neutralgeneral
UBS lowers Syndax Pharmaceuticals price target on revenue outlook
Investing.com Analyst Ratings34 · bearishanalyst
Syndax price target lowered to $33 from $37 at UBS
The Fly38 · neutralanalyst
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?
Yahoo Top42 · neutralearnings
Syndax (SNDX) Q2 2026 Earnings Call Transcript
The Motley Fool73 · bullishearnings
Syndax price target lowered to $40 from $44 at JPMorgan
The Fly36 · neutralanalyst
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
Syndax Pharmaceuticals stock price target lowered to $26 by BofA
Investing.com Analyst Ratings34 · bearishanalyst
Syndax sees Revuforj U.S. peak net revenue in excess of $2B as Q4 axatilimab readouts approach
Seeking Alpha67 · bullishproduct/pr
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
Syndax Pharmaceuticals GAAP EPS of -$0.55 misses by $0.09, revenue of $73M misses by $6.33M
Seeking Alpha34 · bearishearnings
Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update
StockTitan55 · neutralearnings
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
StockTitan50 · neutralgeneral
A Fresh Look At Syndax Pharmaceuticals
Seeking Alpha53 · neutralproduct/pr
Syndax Pharmaceuticals, Inc. (SNDX) Discusses Pipeline Expansion and Next Phase of Innovation for Lead Therapies - Slideshow
Seeking Alpha56 · neutralproduct/pr
Syndax Pharmaceuticals Inc (SNDX) files 8-K
SEC 8-K50 · neutralgeneral
Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event | SNDX Stock News
StockTitan63 · neutralproduct/pr
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | SNDX Stock News
StockTitan50 · neutralgeneral
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
Yahoo Top56 · neutralanalyst
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced
Seeking Alpha73 · bullishproduct/pr